Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended September 30, 2020
Issued Date: October 28, 2020
GSK reported resilient performance in Q3 2020, characterized by strong commercial execution in key growth products and disciplined cost control. The company is preparing for the separation of its Biopharma and Consumer Health businesses. The results reflect the ongoing impact of the COVID-19 pandemic, particularly on the Vaccines business, though vaccination rates showed recovery in the quarter.
Key Financial Metrics
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| Turnover | £8.6 billion | £9.4 billion | £25.4 billion | £24.9 billion |
| Total Operating Profit | £1.9 billion | £2.1 billion | £6.7 billion | £5.1 billion |
| Adjusted Operating Profit | £2.7 billion | £2.8 billion | £7.1 billion | £7.1 billion |
| Total EPS | 25.0p | 31.4p | 102.0p | 67.7p |
| Adjusted EPS | 35.6p | 38.6p | 92.6p | 99.2p |
| Net Cash from Operations | £0.9 billion | £2.5 billion | £4.6 billion | £4.6 billion |
| Free Cash Flow | (£0.2) billion | £1.9 billion | £2.3 billion | £2.5 billion |
| Net Debt | £23.9 billion | £28.1 billion | £23.9 billion | £28.1 billion |
Note: Growth rates are provided in the text as Actual Exchange Rate (AER) and Constant Exchange Rate (CER). Q3 Turnover declined 8% AER (-3% CER). 9M Turnover increased 2% AER (4% CER).
Material Changes vs. Prior Period
- Revenue Mix: Pharmaceuticals sales declined 7% AER (-3% CER) in Q3, driven by declines in Established Pharmaceuticals (-23% AER) and HIV (-4% AER), partially offset by strong growth in Respiratory (+21% AER) and Oncology (+55% AER). Vaccines sales fell 12% AER (-9% CER) due to COVID-19 impacts on Shingrix and established vaccines. Consumer Healthcare sales grew 2% CER in Q3, driven by the inclusion of the Pfizer portfolio.
- Profitability: Total EPS decreased 20% AER in Q3, primarily due to higher re-measurement charges on contingent consideration liabilities and an adverse comparison to Hindustan Unilever share value gains in 2019. Adjusted EPS declined 8% AER but grew 1% CER, reflecting operating profit growth offset by a higher effective tax rate.
- Cash Flow: Q3 Free Cash Flow turned negative (£-0.2 billion) compared to a £1.9 billion inflow in Q3 2019, driven by increased trade receivables, inventory build-up in Vaccines, and higher dividends to non-controlling interests.
- Divestments: The nine-month period included a significant gain from the disposal of Horlicks and other Consumer Healthcare brands to Unilever, contributing to the increase in Total EPS for the nine-month period.
Guidance, Outlook, and Risks
- 2020 Guidance: GSK remains on track to deliver full-year 2020 Adjusted EPS at the lower end of the previously stated range of -1% to -4% at CER. This outlook assumes a sustained recovery in adult immunization rates, particularly for Shingrix.
- Pipeline Progress: Three new approvals were secured since Q2: Blenrep (multiple myeloma), Trelegy (asthma indication), and Nucala (Hypereosinophilic Syndrome). Positive European CHMP opinions were received for long-acting HIV regimens and Zejula (ovarian cancer).
- COVID-19 Solutions: Phase I/II trials for the Sanofi-GSK vaccine candidate have initiated, with Phase III expected in December 2020. Supply agreements have been reached with the US, EU, UK, and Canada. Phase III trials for the VIR-7831 antibody therapy are underway.
- Risks: The filing highlights the uncertainty of the COVID-19 pandemic's duration and impact on trading results, clinical trials, and supply continuity. Currency fluctuations (strengthening Sterling) continue to negatively impact reported growth. Significant legal proceedings and contingent consideration liabilities remain key financial risks.
Investor Verification Checklist
- Contingent Consideration Liability: Verify the impact of the £339 million re-measurement charge in Q3 related to the Shionogi-ViiV Healthcare joint venture and its effect on Total EPS versus Adjusted EPS.
- Vaccines Recovery: Monitor the sustainability of the recovery in adult immunization rates and Shingrix prescription levels, which are critical to meeting the 2020 guidance.
- Consumer Healthcare Separation: Review the progress of the separation preparation program and the associated one-time costs (estimated at £600-700 million) impacting future margins.
- Free Cash Flow Conversion: Assess the drivers behind the negative Q3 free cash flow, specifically the increase in trade receivables and inventory, to ensure liquidity remains robust.
- Pro-Forma Metrics: Distinguish between reported growth and pro-forma growth (which includes Pfizer Consumer Healthcare results in the prior year) to accurately assess organic performance trends.